Published in J Am Soc Nephrol on June 18, 2008
Immune Monitoring as Prerequisite for Transplantation Tolerance Trials. Clin Exp Immunol (2017) 0.84
Cost-effectiveness of modern mTOR inhibitor based immunosuppression compared to the standard of care after renal transplantation in Germany. Eur J Health Econ (2014) 0.77
The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable? Curr Transplant Rep (2015) 0.75
A prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation. J Transplant (2012) 0.75
The practical utility of an economic analysis of calcineurin withdrawal following renal transplantation. J Am Soc Nephrol (2008) 0.75
Estimating Health-State Utility Values in Kidney Transplant Recipients and Waiting-List Patients Using the EQ-5D-5L. Value Health (2017) 0.75
Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med (1999) 15.69
A study of the quality of life and cost-utility of renal transplantation. Kidney Int (1996) 4.51
Diabetes mellitus after kidney transplantation in the United States. Am J Transplant (2003) 4.39
Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant (2004) 4.04
Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant (2003) 2.22
Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int (2002) 2.10
Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol (2000) 1.90
Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation (2001) 1.85
Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant (2006) 1.83
Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med (1987) 1.53
Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant (2005) 1.53
Payment for living donor (vendor) kidneys: a cost-effectiveness analysis. Am J Transplant (2004) 1.45
Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant. Am J Transplant (2004) 1.33
Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation (2002) 1.26
The expanded criteria donor dilemma in cadaveric renal transplantation. Transplantation (2003) 1.22
A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation (2005) 1.14
Kidney transplantation in the elderly: a decision analysis. J Am Soc Nephrol (2003) 1.13
Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol (2004) 1.12
Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant (2004) 1.12
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int (2005) 0.97
A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation (2004) 0.96
Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation (2003) 0.94
Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom. Clin Ther (2005) 0.91
Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant (2004) 0.89
Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant (2004) 0.88
Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol (2004) 0.87
Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK. Pharmacoeconomics (2006) 0.86
Induction versus noninduction therapy in kidney transplantation: considering different PRA levels and different induction therapies. Transplant Proc (2004) 0.86
Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int (2001) 0.85
Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years. Clin Transplant (2007) 0.84
Cost-effectiveness of sirolimus therapy with early cyclosporin withdrawal vs. long-term cyclosporin therapy in Australia. Clin Transplant (2006) 0.83
Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. Transplantation (2003) 0.81
Multivariate analysis of antibody induction therapy and their associated outcomes in deceased donor transplants. Transplant Proc (2005) 0.80
Consequences of eliminating HLA-B in deceased donor kidney allocation to increase minority transplantation. Am J Transplant (2005) 0.79
Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety. Am J Kidney Dis (2001) 0.79
Renal function: defining long-term success. Nephrol Dial Transplant (2004) 0.79
Basiliximab plus low-dose cyclosporin vs. OKT3 for induction immunosuppression following renal transplantation. Clin Transplant (2003) 0.79
Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect. Drugs Aging (2004) 0.79
Racial variation in medical outcomes among living kidney donors. N Engl J Med (2010) 3.60
Early mobilization of patients hospitalized with community-acquired pneumonia. Chest (2003) 2.85
Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant (2005) 2.76
Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine (2012) 2.43
Liver transplantation cost in the model for end-stage liver disease era: looking beyond the transplant admission. Liver Transpl (2009) 2.38
Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant (2003) 2.22
Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant (2005) 2.19
Sensitivity of billing claims for cardiovascular disease events among kidney transplant recipients. Clin J Am Soc Nephrol (2009) 2.17
Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol (2004) 1.93
The interaction among donor characteristics, severity of liver disease, and the cost of liver transplantation. Liver Transpl (2011) 1.79
Nomogram for predicting the likelihood of delayed graft function in adult cadaveric renal transplant recipients. J Am Soc Nephrol (2003) 1.77
Bariatric surgery among kidney transplant candidates and recipients: analysis of the United States renal data system and literature review. Transplantation (2009) 1.75
Health insurance considerations for adolescent transplant recipients as they transition to adulthood. Pediatr Transplant (2007) 1.68
Leaving family for work: ambivalence and mental health among Mexican migrant farmworker men. J Immigr Minor Health (2006) 1.57
Clinical and economic burden of pneumococcal disease in older US adults. Vaccine (2010) 1.55
Race, Relationship and Renal Diagnoses After Living Kidney Donation. Transplantation (2015) 1.45
Transplant certification and quality assessment: time to take the front line? Prog Transplant (2013) 1.43
Outcomes in kidney transplant recipients from older living donors. Transplantation (2015) 1.42
Cost Implications of New National Allocation Policy for Deceased Donor Kidneys in the United States. Transplantation (2016) 1.42
Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant. Am J Transplant (2004) 1.33
The interplay of socioeconomic status, distance to center, and interdonor service area travel on kidney transplant access and outcomes. Clin J Am Soc Nephrol (2010) 1.32
Resource utilization in patients hospitalized with heart failure: insights from a contemporary national hospital database. Am Heart J (2008) 1.27
Consistency of racial variation in medical outcomes among publicly and privately insured living kidney donors. Transplantation (2014) 1.22
Delivery patterns of recommended chronic kidney disease care in clinical practice: administrative claims-based analysis and systematic literature review. Clin Exp Nephrol (2008) 1.21
Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. Am J Kidney Dis (2008) 1.20
The implications of acute rejection for allograft survival in contemporary U.S. kidney transplantation. Transplantation (2012) 1.14
Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation (2006) 1.13
Agreement of immunosuppression regimens described in Medicare pharmacy claims with the Organ Procurement and Transplantation Network survey. J Am Soc Nephrol (2006) 1.13
Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation. Clin J Am Soc Nephrol (2005) 1.11
Renal function and healthcare costs in patients with polycystic kidney disease. Clin J Am Soc Nephrol (2010) 1.10
De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications. Am J Kidney Dis (2005) 1.09
Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population. J Am Geriatr Soc (2012) 1.07
The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant (2004) 1.07
Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation (2004) 1.07
Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation (2007) 1.06
Early clinical complications after ABO-incompatible live-donor kidney transplantation: a national study of Medicare-insured recipients. Transplantation (2014) 1.04
Novel methods for tracking long-term maintenance immunosuppression regimens. Clin J Am Soc Nephrol (2007) 1.04
Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med (2008) 1.03
Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure. Clin J Am Soc Nephrol (2008) 1.02
The implications of acute rejection and reduced allograft function on health care expenditures in contemporary US kidney transplantation. Transplantation (2012) 1.00
Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider. Am J Kidney Dis (2011) 1.00
A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation (2008) 0.99
Kidney transplant Medicare payments and length of stay: associations with comorbidities and organ quality. Arch Med Sci (2011) 0.99
Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA (2006) 0.98
Following the organ supply: assessing the benefit of inter-DSA travel in liver transplantation. Transplantation (2013) 0.98
Chronic inotropic therapy in end-stage heart failure. Am Heart J (2006) 0.98
Marine diatom, Navicula sp. strain JPCC DA0580 and marine green alga, Chlorella sp. strain NKG400014 as potential sources for biodiesel production. Appl Biochem Biotechnol (2009) 0.98
Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int (2004) 0.97
Clinical features of suicide attempts in adults with autism spectrum disorders. Gen Hosp Psychiatry (2012) 0.97
Characterization of marine microalga, Scenedesmus sp. strain JPCC GA0024 toward biofuel production. Biotechnol Lett (2009) 0.97
Obesity and cardiac risk after kidney transplantation: experience at one center and comprehensive literature review. Transplantation (2008) 0.96
Community-acquired pneumonia: symptoms and burden of illness at diagnosis among US adults aged 50 years and older. Patient (2013) 0.96
Ethnic disparities in health-related quality of life among older rural adults with diabetes. Ethn Dis (2007) 0.95
The relationship between temporal changes in blood pressure and changes in cognitive function: atherosclerosis risk in communities (ARIC) study. Prev Med (2002) 0.92
Depression diagnoses after living kidney donation: linking U.S. Registry data and administrative claims. Transplantation (2012) 0.92
Thymoglobulin induction is safe and effective in live-donor renal transplantation: a single center experience. Transplantation (2006) 0.91
Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction. Am J Transplant (2002) 0.90
Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol (2004) 0.90
Cardiac evaluation before kidney transplantation: a practice patterns analysis in Medicare-insured dialysis patients. Clin J Am Soc Nephrol (2008) 0.90
Frequency and clinical features of patients who attempted suicide by charcoal burning in Japan. J Affect Disord (2012) 0.90
Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value Health (2007) 0.90
Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2006) 0.89
Influence of early posttransplantation prednisone and calcineurin inhibitor dosages on the incidence of new-onset diabetes. Clin J Am Soc Nephrol (2007) 0.89
Exercise during hemodialysis decreases the use of antihypertensive medications. Am J Kidney Dis (2002) 0.89
Isolation and characterization of antibodies against three consecutive Tn-antigen clusters from a phage library displaying human single-chain variable fragments. J Biochem (2010) 0.89
The cost effectiveness of deceased organ donation. Transplantation (2005) 0.89
Novel carbohydrate-binding activity of pancreatic trypsins to N-linked glycans of glycoproteins. J Biol Chem (2006) 0.89
An azoreductase, aerobic NADH-dependent flavoprotein discovered from Bacillus sp.: functional expression and enzymatic characterization. Appl Microbiol Biotechnol (2007) 0.88
Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol (2006) 0.88
The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology (Oxford) (2009) 0.87
Maintenance immunosuppression use and the associated risk of avascular necrosis after kidney transplantation in the United States. Transplantation (2005) 0.87
Health-related quality of life in kidney transplant patients with diabetes. Clin Transplant (2013) 0.87
Obesity and kidney transplant candidates: how big is too big for transplantation?. Am J Nephrol (2012) 0.86
The impact of kidney transplantation on heart failure risk varies with candidate body mass index. Am Heart J (2009) 0.86
Identification of the catalytic acid base residue of arthrobacter endo-beta-N-acetylglucosaminidase by chemical rescue of an inactive mutant. J Biochem (2007) 0.86
Understanding antihypertensive medication use after living kidney donation through linked national registry and pharmacy claims data. Am J Nephrol (2014) 0.86
A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev (2004) 0.85
Overproduction of anti-Tn antibody MLS128 single-chain Fv fragment in Escherichia coli cytoplasm using a novel pCold-PDI vector. Protein Expr Purif (2012) 0.85
Increased risk of graft failure in kidney transplant recipients after a diagnosis of dyspepsia or gastroesophageal reflux disease. Transplantation (2008) 0.84
Cancer diagnoses after living kidney donation: linking U.S. Registry data and administrative claims. Transplantation (2012) 0.84
Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. Am J Transplant (2004) 0.83
Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol (2008) 0.83
Cognitive functioning as a predictor of ischemic stroke incidence. Epidemiology (2003) 0.83
Renal graft survival and calcineurin inhibitor. Transplantation (2005) 0.82
Incremental value of the pancreas allograft to the survival of simultaneous pancreas-kidney transplant recipients. Diabetes Care (2009) 0.82
Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis Rheum (2006) 0.82
Flow cytometry crossmatch before kidney transplantation in contemporary practice: target cell utilization, results patterns, and associated long-term graft survival. Clin Transpl (2008) 0.82
Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons. Transplantation (2009) 0.81
Short-term mortality and cost associated with cardiac device implantation in patients hospitalized with heart failure. Am Heart J (2008) 0.81
Synthesis of CMP-9''-modified-sialic acids as donor substrate analogues for mammalian and bacterial sialyltransferases. Carbohydr Res (2007) 0.81
Associations of recipient illness history with hypertension and diabetes after living kidney donation. Transplantation (2011) 0.81
Quantifying prognostic impact of prescription opioid use before kidney transplantation through linked registry and pharmaceutical claims data. Transplantation (2015) 0.81
Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients. Pharmacoeconomics (2008) 0.81
Gout after living kidney donation: correlations with demographic traits and renal complications. Am J Nephrol (2015) 0.80
Variation in Cost and Quality in Kidney Transplantation. Transplantation (2015) 0.80
Effect of heparin addition on expansion of cord blood hematopoietic progenitor cells in three-dimensional coculture with stromal cells in nonwoven fabrics. J Artif Organs (2004) 0.80
Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients. Transplantation (2009) 0.80
Cardioprotective medication use after acute myocardial infarction in kidney transplant recipients. Transplantation (2011) 0.80